News&PR
Featured news
The world’s first Ultrasound AI software for blood clots obtains EU Approval
ThinkSono Partners With NYU Langone Health to Conduct Study of Ultrasound AI Guidance Software for DVT Detection
Temple Health Joins U.S. Study of Artificial Intelligence Diagnostic System for DVT Detection
All News
ThinkSono selected in the UK’s top 100 AI scale ups
ThinkSono Obtains FDA Breakthrough Device Designation
ThinkSono Raises $6M — What’s next?
ThinkSono Secures Additional £4.5M / $6Mn Funding, Expands Team and Operations Across the UK, EU and U.S.
UW Health - Clinical study tests AI-guided ultrasound to detect deep vein thrombosis
Allegheny General Hospital First in Western PA to Participate in Clinical Trial Using Artificial Intelligence to Detect Deep Vein Thrombosis in Cardiac Patients
Temple Health Joins U.S. Study of Artificial Intelligence Diagnostic System for DVT Detection
Fouad Noor presents ThinkSono at LSI Europe 2023
ThinkSono Joins Butterfly Garden to Deploy ThinkSono AI on Butterfly’s Imaging Platform
Regulatory Approval & Compliance
ThinkSono Guidance is currently only CE IIb marked for clinical use in the EU and UK. It is not FDA approved. Please contact ThinkSono for more information. The CE Class IIb intended purpose of ThinkSono Guidance is found in the instructions for use (IFU). ThinkSono Guidance EU manufacturer is ThinkSono GmbH (EUDAMED SRN number: DE-MF-000034914). To buy and use ThinkSono Guidance please send an email to hello@thinksono.com